Latest period
$207.10M
YoY change
+53.4%
5Y CAGR
+2.8%
Peak year (2025)
$191.60M
Cumulative CapEx
$1.40B
CapEx history chart for Insulet (PODD) from 2004 to 2025
Latest: $191.60M
CapEx growth chart for Insulet (PODD) from 2004 to 2025
Latest: +53.4%
CapEx history table for Insulet (PODD) from 2004 to 2025
| 2025 | $191.60M | +53.4% | +$66.70M | ||
| 2024 | $124.90M | +65.2% | +$49.30M | ||
| 2023 | $75.60M | -51.9% | −$81.70M | ||
| 2022 | $157.30M | +28.2% | +$34.60M | ||
| 2021 | $122.70M | -26.3% | −$43.80M | ||
| 2020 | $166.50M | -2.6% | −$4.40M | ||
| 2019 | $170.90M | +5.3% | +$8.55M | ||
| 2018 | $162.35M | +110.2% | +$85.13M | ||
| 2017 | $77.23M | +249.2% | +$55.11M | ||
| 2016 | $22.11M | +108.5% | +$11.51M | ||
| 2015 | $10.61M | -7.6% | −$878.00K | ||
| 2014 | $11.49M | +57.2% | +$4.18M | ||
| 2013 | $7.31M | -33.5% | −$3.68M | ||
| 2012 | $10.99M | -1.1% | −$123.00K | ||
| 2011 | $11.11M | +69.7% | +$4.57M | ||
| 2010 | $6.55M | +108.6% | +$3.41M | ||
| 2009 | $3.14M | -68.7% | −$6.91M | ||
| 2008 | $10.05M | -0.4% | −$42.00K | ||
| 2007 | $10.09M | -23.2% | −$3.05M | ||
| 2006 | $13.14M | +140.1% | +$7.67M | ||
| 2005 | $5.47M | +102.1% | +$2.76M | ||
| 2004 | $2.71M | — | — |
- 2025$191.60M+53.4%
- 2024$124.90M+65.2%
- 2023$75.60M-51.9%
- 2022$157.30M+28.2%
- 2021$122.70M-26.3%
- 2020$166.50M-2.6%
- 2019$170.90M+5.3%
- 2018$162.35M+110.2%
- 2017$77.23M+249.2%
- 2016$22.11M+108.5%
- 2015$10.61M-7.6%
- 2014$11.49M+57.2%
- 2013$7.31M-33.5%
- 2012$10.99M-1.1%
- 2011$11.11M+69.7%
- 2010$6.55M+108.6%
- 2009$3.14M-68.7%
- 2008$10.05M-0.4%
- 2007$10.09M-23.2%
- 2006$13.14M+140.1%
- 2005$5.47M+102.1%
- 2004$2.71M—
CapEx values are taken from Insulet's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Insulet (PODD)
According to Insulet's latest reported financial statements, the company's current CapEx (TTM) is $207.10M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Insulet (PODD) CapEx totalled $191.60M – surged 53.4% year-over-year.
Through 2020–2025 (5 years), Insulet CapEx delivered a +2.8% annualised rate; sustaining 2 straight years of year-over-year growth.
2025 marks the peak CapEx at $191.60M, with the historical low of $2.71M recorded in 2004.
Insulet Capital Expenditures by Year
Insulet Capital Expenditures 2025: $191.60M
Insulet posted CapEx of $191.60M in 2025, surged 53.4% from 2024. This figure represents the highest annual value in the available history.
Insulet Capital Expenditures 2024: $124.90M
In 2024, Insulet reported CapEx of $124.90M, surged 65.2% from 2023.
Insulet Capital Expenditures 2023: $75.60M
Insulet CapEx in 2023 was $75.60M, plunged 51.9% below 2022.
Insulet Capital Expenditures 2022: $157.30M
2022's CapEx for Insulet came in at $157.30M, grew 28.2% from 2021.
Insulet Capital Expenditures 2021: $122.70M
Insulet CapEx in 2021 was $122.70M.
See more financial history for Insulet (PODD).
Sector peers by CapEx
Healthcare peers of Insulet (PODD), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Insulet (PODD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation